Comparing 2 hypotheses side-by-side
Heparan sulfate and other glycosaminoglycans serve as nucleation templates that facilitate cross-seeding by concentrating different amyloidogenic proteins and stabilizing cross-β structures. Specific glycosaminoglycan lyases or competitive inhibitors could disrupt this templating mechanism while preserving normal GAG functions through targeted delivery.
Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | Glycosaminoglycan Template Dis | Transglutaminase-2 Cross-Linki |
|---|---|---|
| Mechanistic | 0.700 | 0.750 |
| Evidence | 0.650 | 0.600 |
| Novelty | 0.750 | 0.700 |
| Feasibility | 0.600 | 0.800 |
| Impact | 0.650 | 0.700 |
| Druggability | 0.700 | 0.850 |
| Safety | 0.550 | 0.650 |
| Competition | 0.700 | 0.750 |
| Data | 0.650 | 0.700 |
| Reproducible | 0.700 | 0.750 |
| KG Connect | 0.673 | 0.742 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["HSPG2 perlecan
extracellular matrix"] --> B["Heparan sulfate chains
polyanionic surface"]
B --> C["Electrostatic attraction
of amyloidogenic proteins"]
C --> D["Alpha-synuclein
monomer binding"]
C --> E["Amyloid-beta
monomer binding"]
C --> F["Tau protein
monomer binding"]
D --> G["Local concentration
micromolar range"]
E --> G
F --> G
G --> H["Nucleation template
0.5-1.0 nm sulfate spacing"]
H --> I["Conformational catalysis
beta-sheet formation"]
I --> J["Cross-beta amyloid
fibril assembly"]
J --> K["Cross-seeding between
different amyloid species"]
K --> L["Synaptic dysfunction
and neuroinflammation"]
L --> M["Progressive neuronal
death and degeneration"]
N["Glycosaminoglycan lyases
targeted delivery"] -->|"disrupts"| H
O["Competitive GAG inhibitors
heparin mimetics"] -->|"blocks"| C
N --> P["Preserved normal
GAG functions"]
O --> P
classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8
class A,B,G,H normal
class N,O,P therapeutic
class J,K,L,M pathology
class I outcome
class C,D,E,F molecular
graph TD
A["""Neuroinflammation
& Calcium Dysregulation"""] -->|"Ca2+ Influx"| B["TG2 Activation
(Transglutaminase-2)"]
B -->|"Isopeptide Bond
Formation"| C["Tau Cross-Linking
& Aggregation"]
B -->|"Protein Cross-Linking"| D["Abeta Oligomer
Stabilization"]
B -->|"ECM Cross-Linking"| E["BBB Disruption
& Matrix Stiffening"]
B -->|"NF-kappaB Activation"| F["Pro-inflammatory
Cytokine Cascade"]
C --> G["Neurofibrillary
Tangle Formation"]
D --> H["Amyloid Plaque
Stabilization"]
E --> I["Peripheral Immune
Cell Infiltration"]
F --> J["Chronic
Neuroinflammation"]
G --> K["Neuronal Death
& Cognitive Decline"]
H --> K
I --> J
J --> K
L["""TG2 Inhibitor
Therapy"""] -->|"Selective Active-Site
Blockade"| M["TG2 Cross-Linking
Inhibition"]
M -->|"Reduced Tau
Cross-Linking"| N["Prevented Tangle
Formation"]
M -->|"Reduced Abeta
Stabilization"| O["Enhanced Abeta
Clearance"]
M -->|"Preserved BBB
Integrity"| P["Reduced Immune
Infiltration"]
M -->|"Suppressed NF-kappaB"| Q["Reduced
Neuroinflammation"]
N --> R["Neuroprotection &
Cognitive Preservation"]
O --> R
P --> R
Q --> R
style A fill:#ff8a80,stroke:#d32f2f,color:#000
style L fill:#4fc3f7,stroke:#2196f3,color:#000
style R fill:#81c784,stroke:#4caf50,color:#000
style K fill:#ffab91,stroke:#e64a19,color:#000